Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®). HTA ID: 23002

Assessment Status NCPE assessment ongoing
HTA ID 23002
Drug Lutetium (177Lu) vipivotide tetraxetan
Brand Pluvicto®
Indication Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.
Assessment Process
Rapid review commissioned 09/01/2023
Rapid review completed 10/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/03/2023
Pre-submission consultation with Applicant 09/05/2023
Full submission received from Applicant 19/07/2023
Preliminary review sent to Applicant 06/02/2024
NCPE assessment re-commenced 05/03/2024
Factual accuracy sent to Applicant 11/07/2024
NCPE assessment re-commenced 19/07/2024